Last updated: May 27, 2026
BRIVIACT (brivaracetam) is supplied by the UCB group, with manufacturing and finished-dose supply distributed across UCB manufacturing sites and third-party suppliers used for drug substance, intermediates, and/or finished product. Public procurement and regulatory listings determine the “true” supplier per market and dosage form, because the same brand can be sourced from different plants depending on country and pack strength.
Who supplies BRIVIACT to pharmacies and hospitals?
Answer: BRIVIACT is marketed and supplied by UCB in most jurisdictions. The downstream “supplier” to hospitals and pharmacies is typically the local UCB affiliate and/or the authorized national wholesaler network that holds the product authorization and distribution rights.
What is the supplier structure for BRIVIACT?
- Marketing authorization holder (MAH): UCB (varies by country affiliate name).
- Finished dose supply: UCB manufacturing sites or contract manufacturing organizations (CMOs) for finished product, packaging, or both.
- Chain of distribution: national wholesalers licensed under local distribution rules, then pharmacies/hospitals.
Which dosage forms matter for supplier mapping?
Supplier assignments frequently differ by:
- oral tablets (strength-specific)
- oral solution (if marketed in the jurisdiction)
- packaging configuration (blister vs bottle, pack size)
What manufacturers produce BRIVIACT drug substance and intermediates?
Answer: Brivaracetam drug substance is produced via chemical synthesis routes at UCB-affiliated manufacturing and/or qualified external suppliers. Exact plant-level assignment depends on jurisdiction, current commercial sourcing, and contract scope (API only vs API plus intermediate supply).
Common supplier categories used in brivaracetam production
- API manufacturing sites (drug substance)
- Intermediate suppliers (key intermediates used upstream)
- Finished product CMOs (tablet/solution manufacturing and compression/fill-finish)
Which companies are listed as manufacturers on regulatory filings for BRIVIACT?
Answer: The named “manufactured by” entities on regulatory submissions and product leaflets are the best starting point to identify specific manufacturing sites for each market and dosage form. For brivaracetam, those listings typically include:
- UCB manufacturing entities
- qualified third-party manufacturers where contracted
Where those listings usually appear
- EU product information (SmPC) manufacturer section
- national product leaflets
- FDA labeling (for US if applicable) and application correspondence (site listing)
- regulatory approval documents tied to each strength and presentation
What is the Orange Book status of BRIVIACT (brivaracetam) in the US?
Answer: BRIVIACT’s US status is governed by FDA’s drug approval records and exclusivity/patent listings for the approved NDA product. The practical question for suppliers and competitors is whether there are Orange Book-listed patents that constrain generic entry and whether US supply is tied to the NDA’s approved manufacturing sites.
What supplier impact does Orange Book tie to?
- NDA manufacturing site control remains with the approved application.
- Generic manufacturers can produce only after ANDA approval and patent/market exclusivity resolution.
- If patents cover critical manufacturing, formulation, or use, supplier switching for generics is delayed.
When does BRIVIACT lose exclusivity and how does that affect suppliers?
Answer: BRIVIACT’s exclusivity and patent expirations, by country, determine when additional branded supply chains and generic supply can enter. Until then, procurement generally stays in UCB’s commercial supply channels plus contracted plants supporting the NDA/MAH.
What typically drives the exclusivity timeline for branded antiepileptics
- patent expirations on composition, crystalline forms (if any), and formulations
- pediatric exclusivity extensions (where applicable)
- second medical use patents
- regulatory exclusivity categories tied to the NDA/MAH
What generic and biosimilar risks exist for BRIVIACT supply?
Answer: BRIVIACT is a small-molecule antiepileptic. Biosimilar risk is not applicable. Generic entry risk depends on Paragraph IV and ANDA approvals, which determine when alternative manufacturers can supply.
How generic entry changes the supplier landscape
- additional finished-dose manufacturers appear on market shelves after ANDA launch
- price competition pulls purchasing toward lower-cost suppliers
- manufacturing capacity shifts across multiple qualified plants
Which suppliers can replace BRIVIACT if supply is disrupted?
Answer: Replacement is governed by regulatory substitution rules, interchangeability, and product availability per jurisdiction. Substitution typically means:
- a different brivaracetam manufacturer (generic) only after regulatory approval
- or a different presentation strength from the same approved supplier chain
Practical constraints
- patient switching rules in epilepsy care
- pharmacist substitution policies by country
- supply chain lead times for tablet blistering vs solution fill-finish
Key Takeaways
- BRIVIACT is marketed and supplied by the UCB group; market-level distribution is handled through local affiliates and licensed wholesalers.
- True “supplier” varies by country and dosage form because finished product and packaging can be sourced from different UCB sites and qualified CMOs.
- Competitive supplier options expand only after Orange Book or equivalent patent and exclusivity constraints clear for each jurisdiction.
- Branded supply stays concentrated until generic launch and regulatory substitutions begin.
FAQs
- Who is the marketing authorization holder for BRIVIACT in the EU and how does that map to suppliers?
- Which manufacturing sites are listed for BRIVIACT tablets versus oral solution in SmPC product information?
- Do UCB use contract manufacturers for brivaracetam tablets, or is it produced only in-house?
- What happens to BRIVIACT procurement when generic brivaracetam launches in a country?
- Are there different suppliers for different pack sizes or blister vs bottle presentations of BRIVIACT?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-05-27). https://www.accessdata.fda.gov/scripts/cder/daf/
- European Medicines Agency (EMA). EPAR for BRIVIACT (brivaracetam). (Accessed 2026-05-27). https://www.ema.europa.eu/
